Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
We aimed to compare the recommendations of the Korean Medication Algorithm Project for Depressive Disorder 2012 (KMAP-DD2012) with other recently published treatment guidelines for depressive disorder. We reviewed a total of five recently published globaltreatment guidelines and compared each treatment recommendation of the KMAP-DD 2012 with those in other guidelines. For initialtreatment recommendations, there were no significant major differences across guidelines. However, in the case of nonresponse or incompleteresponse to initial treatment, the second recommended treatment step varied across guidelines. For maintenance therapy,medication dose and duration differed among treatment guidelines. Further, there were several discrepancies in the recommendationsfor each subtype of depressive disorder across guidelines. For treatment in special populations, there were no significant differences inoverall recommendations. This comparison identifies that, by and large, the treatment recommendations of the KMAP-DD 2012 aresimilar to those of other treatment guidelines and reflect current changes in prescription pattern for depression based on accumulatedresearch data. Further studies will be needed to address several issues identified in our review.
Abstract
We aimed to compare the recommendations of the Korean Medication Algorithm Project for Depressive Disorder 2012 (KMAP-DD2012) with other recently published treatment guidelines for depressive disorder. We reviewed a total of five recently published global treatment guidelines and compared each treatment recommendation of the KMAP-DD 2012 with those in other guidelines. For initialtreatment recommendations, there were no significant major differences across guidelines. However, in the case of nonresponse or incompleteresponse to initial treatment, the second recommended treatment step varied across guidelines. For maintenance therapy,medication dose and duration differed among treatment guidelines. Further, there were several discrepancies in the recommendationsfor each subtype of depressive disorder across guidelines. For treatment in special populations, there were no significant differences inoverall recommendations. This comparison identifies that, by and large, the treatment recommendations of the KMAP-DD 2012 aresimilar to those of other treatment guidelines and reflect current changes in prescription pattern for depression based on accumulatedresearch data. Further studies will be needed to address several issues identified in our review.
참고문헌 (33)
- Keller MB, "Implications of failing to achieve successful long term maintenance treatment of recurrent unipolar major depression", Biol Psychiatry, 44, pp.348~360 (1998)
- Goldberg D, "The “NICE Guideline” on the treatment of depression", Epidemiol Psichiatr Soc, 15, pp.11~15 (2006)
- Gaynes BN, "The STAR*D study: treating depression in the real world", Cleve Clin J Med, 75, pp.57~66 (2008)
- Mathys M, "Targeting treatment-resistant depression", J Pharm Pract, 24, pp.520~533 (2011)
- Fava M, "Definition and epidemiology of treatment-resistant depression", Psychiatr Clin North Am, 19, pp.179~200 (1996)
- Viner MW, "Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation", J Clin Psychopharmacol, 23, pp.104~106 (2003)
- Dunner DL, "Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression:a randomized, open-label, pilot study", J Clin Psychiatry, 68, pp.1071~1077 (2007)
- Papakostas GI, "Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder", J Clin Psychiatry, 66, pp.1326~1330 (2005)
- Adson DE, "Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors", Depress Anxiety, 19, pp.121~126 (2004)
- Barbee JG, "The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder", J Clin Psychiatry, 65, pp.975~981 (2004)
- Meltzer-Brody S, "New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum", Dialogues Clin Neurosci, 13, pp.89~100 (2011)
- Yonkers KA, "Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women", Obstet Gynecol, 117, pp.961~977 (2011)
- Birmaher B, "Practice parameter for the assessment and treatment of children and adolescents with depressive disorders", J Am Acad Child Adolesc Psychiatry, 46, pp.1503~1526 (2007)
- Hughes CW, "Texas Children’s Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder", J Am Acad Child Adolesc Psychiatry, 46, pp.667~686 (2007)
- Taylor WD, "A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future", Neuropsychopharmacology, 29, pp.2285~2299 (2004)
- Dunner DL, "Treatment considerations for depression in the elderly", CNS Spectr, 8(12 Suppl 3), pp.14~19 (2003)
- Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction", J Affect Disord, 117(Suppl 1), pp.S1~S2 (2009)
- Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care", World J Biol Psychiatry, 8, pp.67~104 (2007)
- American Psychiatric Association, "Treatment of Patients with Major Depression and Practical Guideline 3rd Edition" (2010), American Psychiatric Association
- National Collaborating Centre for Mental Health (commissioned by the National Institute for Health & Clinical Excellence), "Depression: the treatment and management of depression in adults (updated edition)" (2010), The British Psychological Society and The Royal College of Psychiatrists
- Suehs B, "Texas Medication Algorithm Project Procedural Manual Major depressive disorder algorithms" (2008), Texas Department of State health Services
- 안용민, "주요 정신질환의 약물치료에 대한 한국형 알고리듬 개발 (1) - 알고리듬과 임상지침서의 장·단점 및 개발과 관련된 일반사항 -", 대한정신약물학회지, 13(1), pp.18~29 (2002), 대한정신약물학회
- 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)", 신경정신의학, 46(5), pp.453~460 (2007), 대한신경정신의학회
- Nemeroff CB, "Use of atypical antipsychotics in refractory depression and anxiety", J Clin Psychiatry, 66(Suppl 8), pp.13~21 (2005)
- Papakostas GI, "Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major dperessive disorder: a meta-analysis", J Clin Psychiatry, 68, pp.826~831 (2007)
- Papakostas GI, "Aripiprazole augmentation of selective serotonin reuptake inhibitors for treamtent-resistant major depressive disorder", J Clin Psychiatry, 66, pp.1326~1330 (2005)
- Executive Committee of Korean Medication Algorithm Project for Depressive Disorder 2012, "Korean Medication Guideline for Depressive Disorder 2012" (2012), ML communication
- Canadian Psychiatric Association, "Canadian Network for Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the treatment of depressive disorders", Can J Psychiatry, 46(Suppl 1), pp.5S~90S (2001)
- Sachs GS, "The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000", Postgrad Med, (Spec), pp.1~104 (2000)
- Lam RW, "Canadian Network for Mood and Anxiety Treatments (CANMAT)clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy", J Affect Disord, 117(Suppl 1), pp.S26~S43 (2009)
- 이경욱, "항우울제를 복용 중인 주요 우울증 환자에서 조기 치료 중단율과 위험 요인", 대한정신약물학회지, 17(6), pp.550~556 (2006), 대한정신약물학회
- Kim NS, "Health Services Utilization and Depression Care Quality among Depressed Patients" (2008), Health Insurance Review and Assessment Service
- Joe SH, "A case of morning light treatment for a depressive episode with seasonal pattern", J Korean Neuropsychiatr Assoc, 37, pp.585~592 (1998)